Feature Eiger BioPharma has multiple catalysts in orphan diseases in 2018 By Len Zehrs Despite a failed Phase 2 trial in pulmonary arterial hypertension (PAH), Eiger BioPharmaceuticals (NASDAQ:EIGR) still has multiple shots on goal with its targeted therapies for orphan diseases, including a... February 6, 2018